RankAlpha logo
Back to Rankings

AXGN

AxogenD
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-23
View Chart
Current thesis
The cleanest post-earnings read is that Axogen paired strong top-line growth with better gross margin and enough confidence to raise full-year revenue guidance, while payer coverage and CMS coding tailwinds give the commercial story more substance than a generic medtech growth narrative [#8-K-2026-04-28] [#10-Q-2026-04-28].
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-07-29 · BMO.
What can break
Execution risk remains high around translating payer wins and improved CMS reimbursement into durable case-volume growth rather than a one-quarter sentiment boost.
Momentum
35
Value
47
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $42.00 · Bull $48.00 · Bear $33.00
Earnings
2026-07-29 · BMO
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $50.78
Why
Momentum35 · Δ7d -51.5
Value47 · Δ7d -0.0
Sentiment56 · Δ7d -2.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
35
26% active weight
Current posture
7d trendSoftening
Δ7d
-51.5
Δ21d
-51.7
Value
47
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.3
Sentiment
56
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.8
Δ21d
+8.5
Why this grade

Composite grade D. Momentum 34.8 / Value 47.4 / Sentiment 56.0

Fundamentals (TTM)
As of 2026-07-23
Market Cap
$2.11B
Beta
1.00
Shares Out
53.18M
P/E (TTM) · Derived
-116.5
P/S (TTM)
6.82
P/FCF (TTM)
711.09
Rev YoY
+26.6%
EPS YoY
+347.6%
Gross Margin
+75.0%
Op Margin
+1.8%
Net Debt
$22.1M
Current Ratio
7.10
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology